BioBank Data Exchange connects pharma, biotech, and AI-driven discovery to multi-institutional biospecimen cohorts through governed, consent-aware market infrastructure — unlocking data that was never accessible before.
No existing platform simultaneously provides what BDE delivers. We occupy a structurally uncontested position in the biomedical data ecosystem.
Upstream suppliers — non-commercial, long approval cycles, no cross-institution discovery. BDE: Governance partner, not competitor.
Closed ecosystems, non-neutral incentives, no multi-biobank federation. BDE: Structurally incompatible — we are neutral.
Solve how data is accessed, not which data or under what conditions. BDE: Complements, not competitors.
Lack biospecimen provenance, consent hooks, and clinical depth. BDE: Biologically and operationally superior.
Decades of biospecimen data have accumulated in siloed institutions. The technology to connect them securely now exists. What was missing was neutral market infrastructure — governed, consent-aware, and economically aligned for all participants.
Rapid cohort discovery, biomarker validation, AI/ML training data — through a single governed access layer that cuts timelines from months to days.
A commercial pathway that respects consent frameworks and governance mandates — turning archived collections into sustainable research infrastructure.
Federated, consent-aware discovery. Standards-based interoperability (OMOP, FHIR, GA4GH). Neutral governance that no single participant controls.
AI model performance is now bottlenecked by biologically grounded data. Privacy tech is mature. Biobanks need sustainable models. The moment has arrived.
Whether you’re a biobank, pharma organization, research institution, or potential partner — we’d like to hear from you.
Full access to BDE’s business plan, competitive analysis, market sizing, strategic memos, and live data platform demo — for authorized investors and partners only.
Choose how you'd like to proceed